Advanced

Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.

Mohammad, Aladdin LU ; Smith, Rona M; Chow, Yok W; Chaudhry, Afzal N and Jayne, David R W (2015) In Journal of Rheumatology 42(10). p.1906-1913
Abstract
To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Rheumatology
volume
42
issue
10
pages
1906 - 1913
publisher
J Rheumatol Publ Co
external identifiers
  • pmid:26276966
  • wos:000362234900027
  • scopus:84943224099
ISSN
0315-162X
DOI
10.3899/jrheum.141344
language
English
LU publication?
yes
id
73ecc71e-6c6f-4a26-bef4-f4060adf1666 (old id 7840910)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26276966?dopt=Abstract
date added to LUP
2015-09-06 13:35:15
date last changed
2017-10-22 03:24:35
@article{73ecc71e-6c6f-4a26-bef4-f4060adf1666,
  abstract     = {To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).},
  author       = {Mohammad, Aladdin and Smith, Rona M and Chow, Yok W and Chaudhry, Afzal N and Jayne, David R W},
  issn         = {0315-162X},
  language     = {eng},
  number       = {10},
  pages        = {1906--1913},
  publisher    = {J Rheumatol Publ Co},
  series       = {Journal of Rheumatology},
  title        = {Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.},
  url          = {http://dx.doi.org/10.3899/jrheum.141344},
  volume       = {42},
  year         = {2015},
}